Aridis Pharmaceuticals (NASDAQ:ARDS) Upgraded by Zacks Investment Research to Hold

Share on StockTwits

Zacks Investment Research upgraded shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a sell rating to a hold rating in a report released on Monday, Zacks.com reports.

According to Zacks, “Aridis Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the discovery and development of immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. The company’s product pipeline consists of AR-301, AR-105, AR-101, AR-401, AR-201 and AR-501 which are in clinical stages. Aridis Pharmaceuticals, Inc. is based in San Jose, United States. “

Other research analysts also recently issued research reports about the company. Maxim Group set a $25.00 price objective on Aridis Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, September 3rd. Northland Securities reaffirmed a buy rating and issued a $40.00 price objective on shares of Aridis Pharmaceuticals in a research note on Tuesday, August 13th. ValuEngine raised Aridis Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 1st. Finally, Laidlaw set a $15.00 price objective on Aridis Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of Buy and an average price target of $23.40.

Aridis Pharmaceuticals stock opened at $7.71 on Monday. The business has a 50 day moving average of $9.30 and a 200-day moving average of $9.64. Aridis Pharmaceuticals has a 1 year low of $6.91 and a 1 year high of $13.38. The company has a market capitalization of $76.47 million and a P/E ratio of -1.10.

Aridis Pharmaceuticals (NASDAQ:ARDS) last released its quarterly earnings data on Monday, August 12th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.19). Aridis Pharmaceuticals had a negative net margin of 660.52% and a negative return on equity of 130.22%. As a group, equities research analysts predict that Aridis Pharmaceuticals will post -3.78 EPS for the current fiscal year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Further Reading: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Aridis Pharmaceuticals (ARDS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks Investment Research Downgrades Focus Financial Partners  to Hold
Zacks Investment Research Downgrades Focus Financial Partners to Hold
United Parcel Service  Shares Gap Down to $118.52
United Parcel Service Shares Gap Down to $118.52
Analysts Expect Triumph Bancorp Inc  Will Post Earnings of $0.62 Per Share
Analysts Expect Triumph Bancorp Inc Will Post Earnings of $0.62 Per Share
ZClassic Tops One Day Trading Volume of $508,812.00
ZClassic Tops One Day Trading Volume of $508,812.00
Galactrum  Price Hits $0.0080 on Top Exchanges
Galactrum Price Hits $0.0080 on Top Exchanges
Dent  Price Down 2.8% Over Last 24 Hours
Dent Price Down 2.8% Over Last 24 Hours


© 2006-2019 Ticker Report